About Sarepta Therapeutics, Inc. - Common Stock (SRPT)
Sarepta Therapeutics is a biotechnology company focused on pioneering innovative gene therapies for the treatment of rare genetic diseases, particularly those affecting muscle disorders. The company is dedicated to developing therapies that can enable patients with conditions like Duchenne Muscular Dystrophy to achieve improved outcomes and quality of life. With a strong emphasis on research and development, Sarepta utilizes advanced techniques such as RNA-targeted therapies and gene editing to combat genetic disorders at their source. Through its work, the company aims to transform the landscape of genetic medicine and provide hope for individuals and families affected by these challenging diseases. Read More
NEW YORK - August 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sarepta securities between June 22,2023 and June 24, 2025, both dates inclusive (the “Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK - August 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
NEW YORK - August 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) or PetCo (WOOF) To Contact Him Directly To Discuss Their Options
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
NEW YORK - August 1, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK - July 31, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nasdaq Global Market closes on Wednesday, August 6, 2025. As announced on July 16, 2025, the Company will not be hosting a conference call to discuss results at this time.
The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
